Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mitry, E.
Right arrow Articles by Rougier, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitry, E.
Right arrow Articles by Rougier, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1013-1017, 2004
© 2004 European Society for Medical Oncology

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials

Background: The infusional LV5FU2 and Arbeitsgemeinschaft Internische Onkologie (AIO) regimens are used widely in the treatment of advanced colorectal cancer. Irinotecan combined with these regimens increases survival in front-line treatment. Irinotecan also improves survival in second-line treatment.

Patients and methods: Univariate and multivariate analyses based on the individual data of 602 patients included in two phase III trials were performed to determine predictive factors of survival in advanced colorectal cancer.

Results: Three factors were independently associated with a better progression-free survival: weight loss <5% [hazard ratio (HR) 1.25; 95% confidence interval (CI) 1.00–1.58], World Health Organization performance status (WHO PS) 0–1 (HR 1.29; 95% CI 1.08–1.54) and irinotecan (CPT-11)-containing regimens (HR 1.48; 95% CI 1.03–2.13). Five factors were independently associated with a better overall survival: weight loss <5% (HR 1.67; 95% CI 1.29–2.14), WHO PS 0–1 (HR 1.88; 95% CI 1.27–2.75), one or two metastatic sites (HR 1.24; 95% CI 1.01–1.53), alkaline phosphatase values not over twice the normal range (HR 1.71; 95% CI 1.30–2.24) and CPT-11-containing regimens (HR 1.31; 95% CI 1.07–1.61).

Conclusions: The present analysis confirms that CPT-11-based chemotherapy regimens are independently associated with a better survival in patients with advanced colorectal cancer. Age was not identified as a prognostic factor in this analysis.

E. Mitry1,*, J.-Y. Douillard2, E. Van Cutsem3, D. Cunningham4, E. Magherini5, D. Mery-Mignard5, L. Awad5 and P. Rougier1

1 CHU Ambroise Pare, AP-HP, Boulogne-Billancourt; 2 Centre Rene Gauducheau, Saint-Herblain, France; 3 University Hospital Gasthuisberg, Leuven, Belgium; 4 Royal Marsden Hospital, London, UK; 5 Aventis, Paris, France

*Correspondence to: Dr E. Mitry, Service d'hépato-gastroentérologie et oncologie digestive, CHU Ambroise Paré, AP-HP, 9 avenue Charles de Gaulle, 92100 Boulogne, France. Tel: +33-1-49-09-58-79; Fax: +33-1-49-09-45-08; Email: emmanuel.mitry{at}apr.ap-hop-paris.fr

Key words: chemotherapy, colorectal neoplasms, irinotecan, prognostic factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
Ann. Onc., January 1, 2009; 20(1): 5 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. Machida, T. Yoshino, N. Boku, S. Hironaka, Y. Onozawa, A. Fukutomi, K. Yamazaki, H. Yasui, K. Taku, and M. Asaka
Impact of Baseline Sum of Longest Diameter in Target Lesions by RECIST on Survival of Patients with Metastatic Colorectal Cancer
Jpn. J. Clin. Oncol., October 1, 2008; 38(10): 689 - 694.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. McKibbin, C. R. Frei, R. E. Greene, P. Kwan, J. Simon, and J. M. Koeller
Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting
Oncologist, August 1, 2008; 13(8): 876 - 885.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.-H. Kohne, G. Folprecht, R. M. Goldberg, E. Mitry, and P. Rougier
Chemotherapy in Elderly Patients with Colorectal Cancer
Oncologist, April 1, 2008; 13(4): 390 - 402.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Sorbye, C.-H. Kohne, D. J. Sargent, and B. Glimelius
Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification
Ann. Onc., October 1, 2007; 18(10): 1666 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Gholam, S. Giacchetti, C. Brezault-Bonnet, M. Bouchahda, D. Hauteville, R. Adam, B. Ducot, O. Ghemard, F. Kustlinger, C. Jasmin, et al.
Chronomodulated Irinotecan, Oxaliplatin, and Leucovorin-Modulated 5-Fluorouracil as Ambulatory Salvage Therapy in Patients with Irinotecan- and Oxaliplatin-Resistant Metastatic Colorectal Cancer
Oncologist, November 1, 2006; 11(10): 1072 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. R. Weihrauch, S. Ansen, E. Jurkiewicz, C. Geisen, Z. Xia, K. S. Anderson, E. Gracien, M. Schmidt, B. Wittig, V. Diehl, et al.
Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigen-Derived HLA-A2-Restricted CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer
Clin. Cancer Res., August 15, 2005; 11(16): 5993 - 6001.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Meyerhardt, J. A. Sloan, D. J. Sargent, R. M. Goldberg, M. Pollak, R. F. Morton, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, and C. S. Fuchs
Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer
Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1402 - 1410.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Sastre, E. Marcuello, B. Masutti, M. Navarro, S. Gil, A. Anton, A. Abad, E. Aranda, J. Maurel, M. Valladares, et al.
Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
J. Clin. Oncol., May 20, 2005; 23(15): 3545 - 3551.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Chan and D. J. Kerr
Can we individualise chemotherapy for colorectal cancer?
Ann. Onc., July 1, 2004; 15(7): 996 - 999.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.